Tuesday, 18 Jun 2019

You are here

Best of 2018: Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.

The study was a double-blind, phase 2, randomised, controlled trial of UST vs. PBO in ANA positive, adult SLE patients with moderate-to-severe disease activity.

Patients were randomly assigned (3:2) to the UST or PBO and were stratified according to skin biopsy, nephritis, baseline medications and SLEDAI-2K scores. 

Patients received weight-based initial intravenous infusions followed by subcutaneous injections of UST 90 mg every 8 weeks or placebo parenterally as well. The primary endpoint was a SLEDAI-2K responder index-4 (SRI-4) response at week 24.

Of the 166 patients screened, 102 were randomly assigned to UST (n=60) or PBO (n=42). The week 24 SRI-4 response rates were:

  • UST - 62%
  • PBO - 33% (p=0·006)

Adverse events were similar between groups (78% vs 67%) as were infections (45%] vs 50%). There were no deaths or opportunistic infections.

These data are encouraging for larger phase III trials studying UST in active SLE patients to proceed.

The study was funed by Janssen Research & Development, LLC.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Blinded by the Use of Antimalarials in Lupus?

Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?

Lupus Disease Control with Rituximab

Rituximab (Rituxan) may be an option for maintenance therapy in patients with difficult-to-treat systemic lupus erythematosus (SLE), European researchers reported.

2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.

Lupus Outcomes Influenced by Race/Ethnicity

A lupus registry from San Francisco County analyzed racial/ethnic differences in lupus manifestations and found significant differences in SLE manifestations among racial/ethnic groups. Researchers found that Blacks, Asians/Pacific Islanders (API), and Hispanics are more likely to develop severe manifestations following a diagnosis of SLE. From their database, they identified 724 SLE patients, and identified specific features in different subgroups.

Risk Score Predicts Thrombosis Recurrence in APS

A combination risk score helped predict recurrent thrombosis -- particularly arterial -- among patients with antiphospholipid syndrome (APS), an international study found.